Fig 1. Median PFS for sequential treatments in T790M positive and negative NSCLC patients.
After first generation EGFR-TKI, 22 patients had a T790M and 7 did not. All patients received afatinib, afterwards.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.